stoxline Quote Chart Rank Option Currency Glossary
  
RAPT Therapeutics, Inc. (RAPT)
8.78  -0.15 (-1.68%)    03-28 13:45
Open: 8.86
High: 8.995
Volume: 170,786
  
Pre. Close: 8.93
Low: 8.71
Market Cap: 306(M)
Technical analysis
2024-03-28 1:21:03 PM
Short term     
Mid term     
Targets 6-month :  10.74 1-year :  11.73
Resists First :  9.2 Second :  10.05
Pivot price 8.5
Supports First :  7.82 Second :  6.51
MAs MA(5) :  8.54 MA(20) :  8.61
MA(100) :  17.2 MA(250) :  18.18
MACD MACD :  -1.8 Signal :  -2.4
%K %D K(14,3) :  39.6 D(3) :  31.3
RSI RSI(14): 36.2
52-week High :  27.35 Low :  6.86
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ RAPT ] has closed below upper band by 23.9%. Bollinger Bands are 85.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 9.03 - 9.07 9.07 - 9.11
Low: 8.25 - 8.3 8.3 - 8.34
Close: 8.85 - 8.93 8.93 - 9.01
Company Description

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Headline News

Thu, 28 Mar 2024
JPMorgan Chase & Co. Cuts RAPT Therapeutics (NASDAQ:RAPT) Price Target to $13.00 - Defense World

Wed, 27 Mar 2024
JPMorgan Chase & Co. Cuts RAPT Therapeutics (NASDAQ:RAPT) Price Target to $13.00 - MarketBeat

Fri, 22 Mar 2024
What Makes RAPT Therapeutics (RAPT) an Investment Choice? - Yahoo Finance

Mon, 11 Mar 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc ... - PR Newswire

Thu, 07 Mar 2024
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings? - Yahoo Finance

Thu, 07 Mar 2024
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 35 (M)
Shares Float 28 (M)
Held by Insiders 1.8 (%)
Held by Institutions 102.6 (%)
Shares Short 2,490 (K)
Shares Short P.Month 3,950 (K)
Stock Financials
EPS -3.05
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.26
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -36.2 %
Return on Equity (ttm) -59.6 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.62
Qtrly Earnings Growth 0 %
Operating Cash Flow -97 (M)
Levered Free Cash Flow -54 (M)
Stock Valuations
PE Ratio -2.89
PEG Ratio 0
Price to Book value 2.06
Price to Sales 0
Price to Cash Flow -3.16
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android